theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Alcohol-associated Liver Disease   

Questions discussed in this category


Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?
2 Answers available

What precautions should be taken when discharging a patient from the medical setting on new medication assisted therapy for alcohol use disorder?
This is based on the recent publication by Bernstein et al., PMID 38551564 which investigated the increased rate of initiation of MAUD in the hospital...
5 Answers available
2370520828


Papers discussed in this category


Scientific reports, 2023 Nov 28
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.

JCI insight, 2023 Jun 22
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.

Drug and alcohol dependence, 2024 Sep 07
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

JAMA psychiatry, 2025 Apr 01
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.

Related Topics

  • Hepatology
  • Rheumatology
  • General Rheumatology
  • General Internal Medicine
  • Psychiatry
  • Addiction Psychiatry
  • Hospital Medicine
  • Gastroenterology
  • General Hepatology
  • Primary Care

Copyright © 2025 theMednet
All Rights Reserved.